Literature DB >> 29541822

Is Partial or Total Thyroidectomy Associated with Risk of Long-Term Osteoporosis: A Nationwide Population-Based Study.

Chien-Ling Hung1, Chih-Ching Yeh2,3, Pi-Shan Sung4,5, Chung-Jye Hung1, Chih-Hsin Muo6, Fung-Chang Sung6,7, I-Ming Jou8, Kuen-Jer Tsai9,10.   

Abstract

BACKGROUND: Whether thyroidectomy contributes to osteoporosis (OP) and osteoporotic fracture (OF) is a subject of debate. This study aimed to determine the effect of thyroidectomy on the risk of OP and OF.
METHODS: This retrospective cohort study is based on patient data between January 2000 to December 2005 from the National Health Insurance Research Database. Patients who underwent thyroidectomy were enrolled in the thyroidectomy cohort, and the control cohort was selected by propensity score matching at a ratio of 1:4. Incident OP and OF cases were identified until the end of 2013. The thyroidectomy cohort to control cohort adjusted hazard ratio (aHR) for OP/OF was assessed through multivariable Cox proportional hazard regression analysis.
RESULTS: Totals of 1426 and 5704 patients were included in the thyroidectomy and control cohorts, respectively. The incidence density of OP was higher in the thyroidectomy cohort (7.91/1000 person-years) than in the control cohort (5.98/1000 person-years), with an aHR of 1.43 (95% CI 1.16-1.77, p < 0.05). Younger patients, women, and patients with comorbidities were at a higher risk. The risks of postoperative OP/OF were significantly increased in patients who received thyroxine treatment for more than 1 year, both in the partial thyroidectomy group and in the total and subtotal thyroidectomy group (aHR: 2.47, 95% CI: 1.42-2.31 vs. aHR: 1.84, 95% CI: 1.22-2.76).
CONCLUSION: Thyroidectomy significantly increased the long-term risk of OP. Younger patients, women, patients with comorbidities, and patients receiving chronic thyroxin treatment should be monitored for changes in postoperative bone density.

Entities:  

Mesh:

Year:  2018        PMID: 29541822     DOI: 10.1007/s00268-018-4573-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  24 in total

1.  The effect of thyroid stimulating hormone suppressive therapy on bone geometry in the hip area of patients with differentiated thyroid carcinoma.

Authors:  Jae Hoon Moon; Kyong Yeun Jung; Kyoung Min Kim; Sung Hee Choi; Soo Lim; Young Joo Park; Do Joon Park; Hak Chul Jang
Journal:  Bone       Date:  2015-10-27       Impact factor: 4.398

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.

Authors:  Iwao Sugitani; Yoshihide Fujimoto
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

4.  Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.

Authors:  Laura Y Wang; Andrew W Smith; Frank L Palmer; R Michael Tuttle; Azhar Mahrous; Iain J Nixon; Snehal G Patel; Ian Ganly; James A Fagin; Laura Boucai
Journal:  Thyroid       Date:  2014-12-16       Impact factor: 6.568

5.  Stroke suggests increased risk of dementia.

Authors:  Chih-Yuan Huang; Ying-Chun Li; Hao-Kuang Wang; Pi-Shan Sung; Liang-Chao Wang; Yuan-Ting Sun; Chia-Hsin Pan; Kuen-Jer Tsai
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

6.  Increased Risk of Dementia in Patients with Non-Apnea Sleep Disorder.

Authors:  Pi-Shan Sung; Chih-Ching Yeh; Liang-Chao Wang; Peir-Haur Hung; Chih-Hsin Muo; Fung-Chang Sung; Chih-Hung Chen; Kuen-Jer Tsai
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

7.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks.

Authors:  N D Nguyen; S A Frost; J R Center; J A Eisman; T V Nguyen
Journal:  Osteoporos Int       Date:  2008-03-07       Impact factor: 4.507

Review 8.  Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA).

Authors:  E Hernlund; A Svedbom; M Ivergård; J Compston; C Cooper; J Stenmark; E V McCloskey; B Jönsson; J A Kanis
Journal:  Arch Osteoporos       Date:  2013-10-11       Impact factor: 2.617

Review 9.  Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients.

Authors:  Maria Papaleontiou; Sarah T Hawley; Megan R Haymart
Journal:  Oncologist       Date:  2015-12-09

10.  Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.

Authors:  Chei Won Kim; Seokbo Hong; Se Hwan Oh; Jung Jin Lee; Joo Young Han; Seongbin Hong; So Hun Kim; Moonsuk Nam; Yong Seong Kim
Journal:  J Bone Metab       Date:  2015-08-31
View more
  3 in total

1.  Analyses of the Association between Thyroid Cancer and Osteoporosis/Fracture Histories: A Cross-Sectional Study Using KoGES HEXA Data.

Authors:  Young-Ju Jin; Chang-Myeon Song; Bum-Jung Park; Hyo-Geun Choi
Journal:  Int J Environ Res Public Health       Date:  2021-04-29       Impact factor: 3.390

2.  Total or Near-total Thyroidectomy in treatment of Thyroid Cancer.

Authors:  Gang Li; Lihong Wu
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

3.  Heterogenous biochemical expression of hormone activity in subclinical/overt hyperthyroidism and exogenous thyrotoxicosis.

Authors:  Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich
Journal:  J Clin Transl Endocrinol       Date:  2020-02-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.